Last 12 months
Inside the activity.
0 purchase rows · 6 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 4 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 18, 2021 Filed Feb 22, 2021 23:17 UTC |
Sorg Elaine K.SVP, US Commercial Operations
|
GrantCommon Stock, $0.01 par value | 6,863 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002044 · edgar.xml · nonDerivative · entry 4 Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,751 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:17 UTC |
Sorg Elaine K.SVP, US Commercial Operations
|
GrantCommon Stock, $0.01 par value | 2,530 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002044 · edgar.xml · nonDerivative · entry 3 Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,888 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:17 UTC |
Sorg Elaine K.SVP, US Commercial Operations
|
GrantCommon Stock, $0.01 par value | 1,309 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002044 · edgar.xml · nonDerivative · entry 2 Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,358 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:17 UTC |
Sorg Elaine K.SVP, US Commercial Operations
|
GrantCommon Stock, $0.01 par value | 4,454 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002044 · edgar.xml · nonDerivative · entry 1 Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,049 F1 · shares: . Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:17 UTC |
Hudson Thomas JSVP, R&D and CSO
|
GrantOption(right to buy) · Derivative | 37,267 | $0.00 Strike: $105.92 | $0.00 |
DisclosureSEC source: 0001179110-21-002045 · edgar.xml · derivative · entry 5 Hudson Thomas J · CIK 0001781947 · SVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,267 Underlying: Common stock · 37,267 shares Expires 2031-02-17 F5 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 12,423 on February 18, 2022 12,422 on February 18, 2023, and 12,422 on February 18, 2024. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:17 UTC |
Hudson Thomas JSVP, R&D and CSO
|
GrantCommon Stock, $0.01 par value | 9,483 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002045 · edgar.xml · nonDerivative · entry 4 Hudson Thomas J · CIK 0001781947 · SVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,112 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:17 UTC |
Hudson Thomas JSVP, R&D and CSO
|
GrantCommon Stock, $0.01 par value | 2,530 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002045 · edgar.xml · nonDerivative · entry 3 Hudson Thomas J · CIK 0001781947 · SVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,629 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:17 UTC |
Hudson Thomas JSVP, R&D and CSO
|
GrantCommon Stock, $0.01 par value | 1,240 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002045 · edgar.xml · nonDerivative · entry 2 Hudson Thomas J · CIK 0001781947 · SVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,099 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:17 UTC |
Hudson Thomas JSVP, R&D and CSO
|
GrantCommon Stock, $0.01 par value | 4,216 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002045 · edgar.xml · nonDerivative · entry 1 Hudson Thomas J · CIK 0001781947 · SVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,859 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 18:18 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
GrantOption (Right To Buy) · Derivative | 192,546 | $0.00 Strike: $105.92 | $0.00 |
DisclosureSEC source: 0001179110-21-002046 · edgar.xml · derivative · entry 8 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,546 Underlying: Common stock · 192,546 shares Expires 2031-02-17 F6 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 64,182 on February 18, 2022, 64,182 on February 18, 2023, and 64,182 on February 18, 2024. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 18:18 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
GrantCommon Stock, $0.01 par value | 34,938 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002046 · edgar.xml · nonDerivative · entry 4 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 454,306 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 18:18 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
GrantCommon Stock, $0.01 par value | 29,106 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002046 · edgar.xml · nonDerivative · entry 3 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 419,368 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 18:18 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
GrantCommon Stock, $0.01 par value | 23,605 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002046 · edgar.xml · nonDerivative · entry 2 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 390,262 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 18:18 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
GrantCommon Stock, $0.01 par value | 80,257 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002046 · edgar.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 366,657 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:19 UTC |
Schumacher Laura JVice Chairman
|
GrantOption(right to buy) · Derivative | 65,217 | $0.00 Strike: $105.92 | $0.00 |
DisclosureSEC source: 0001179110-21-002047 · edgar.xml · derivative · entry 5 Schumacher Laura J · CIK 0001319245 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,217 Underlying: Common stock · 65,217 shares Expires 2031-02-17 F5 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 21,739 on February 18, 2022 21,739 on February 18, 2023, and 21,739 on February 18, 2024. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:19 UTC |
Schumacher Laura JVice Chairman
|
GrantCommon Stock, $0.01 par value | 17,468 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002047 · edgar.xml · nonDerivative · entry 4 Schumacher Laura J · CIK 0001319245 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,456 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:19 UTC |
Schumacher Laura JVice Chairman
|
GrantCommon Stock, $0.01 par value | 11,136 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002047 · edgar.xml · nonDerivative · entry 3 Schumacher Laura J · CIK 0001319245 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,988 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:19 UTC |
Schumacher Laura JVice Chairman
|
GrantCommon Stock, $0.01 par value | 8,479 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002047 · edgar.xml · nonDerivative · entry 2 Schumacher Laura J · CIK 0001319245 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,852 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:19 UTC |
Schumacher Laura JVice Chairman
|
GrantCommon Stock, $0.01 par value | 28,832 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002047 · edgar.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,373 F1 · shares: . Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:23 UTC |
SEVERINO MICHAELVice Chairman
|
GrantOption(right to buy) · Derivative | 65,217 | $0.00 Strike: $105.92 | $0.00 |
DisclosureSEC source: 0001179110-21-002049 · edgar.xml · derivative · entry 5 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,217 Underlying: Common stock · 65,217 shares Expires 2031-02-17 F5 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 21,739 on February 18, 2022 21,739 on February 18, 2023, and 21,739 on February 18, 2024. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:23 UTC |
SEVERINO MICHAELVice Chairman
|
GrantCommon Stock, $0.01 par value | 17,468 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002049 · edgar.xml · nonDerivative · entry 4 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,912 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:23 UTC |
SEVERINO MICHAELVice Chairman
|
GrantCommon Stock, $0.01 par value | 10,477 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002049 · edgar.xml · nonDerivative · entry 3 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,444 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:23 UTC |
SEVERINO MICHAELVice Chairman
|
GrantCommon Stock, $0.01 par value | 8,565 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002049 · edgar.xml · nonDerivative · entry 2 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,967 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:23 UTC |
SEVERINO MICHAELVice Chairman
|
GrantCommon Stock, $0.01 par value | 29,121 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002049 · edgar.xml · nonDerivative · entry 1 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,402 F1 · shares: . Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:19 UTC |
Stewart Jeffrey RyanSVP, US Commercial Operations
|
GrantOption (right to buy) · Derivative | 43,478 | $0.00 Strike: $105.92 | $0.00 |
DisclosureSEC source: 0001179110-21-002048 · edgar.xml · derivative · entry 6 Stewart Jeffrey Ryan · CIK 0001761675 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,478 Underlying: Common · 43,478 shares Expires 2031-02-17 F6 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 14,493 on February 18, 2022 14,493 on February 18, 2023, and 14,492 on February 18, 2024. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:19 UTC |
Stewart Jeffrey RyanSVP, US Commercial Operations
|
GrantCommon Stock, $0.01 par value | 7,486 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002048 · edgar.xml · nonDerivative · entry 4 Stewart Jeffrey Ryan · CIK 0001761675 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,699 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:19 UTC |
Stewart Jeffrey RyanSVP, US Commercial Operations
|
GrantCommon Stock, $0.01 par value | 4,176 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002048 · edgar.xml · nonDerivative · entry 3 Stewart Jeffrey Ryan · CIK 0001761675 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,213 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:19 UTC |
Stewart Jeffrey RyanSVP, US Commercial Operations
|
GrantCommon Stock, $0.01 par value | 2,970 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002048 · edgar.xml · nonDerivative · entry 2 Stewart Jeffrey Ryan · CIK 0001761675 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,037 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:19 UTC |
Stewart Jeffrey RyanSVP, US Commercial Operations
|
GrantCommon Stock, $0.01 par value | 10,098 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002048 · edgar.xml · nonDerivative · entry 1 Stewart Jeffrey Ryan · CIK 0001761675 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,067 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:23 UTC |
SALEKI-GERHARDT AZITAEVP, Operations
|
GrantOption(right to buy) · Derivative | 42,236 | $0.00 Strike: $105.92 | $0.00 |
DisclosureSEC source: 0001179110-21-002050 · edgar.xml · derivative · entry 7 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,236 Underlying: Common stock · 42,236 shares Expires 2031-02-17 F7 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 14,079 on February 18, 2022, 14,079 on February 18, 2023, and 14,078 on February 18, 2024. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:23 UTC |
SALEKI-GERHARDT AZITAEVP, Operations
|
GrantCommon Stock, $0.01 par value | 11,229 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002050 · edgar.xml · nonDerivative · entry 4 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,069 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:23 UTC |
SALEKI-GERHARDT AZITAEVP, Operations
|
GrantCommon Stock, $0.01 par value | 5,568 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002050 · edgar.xml · nonDerivative · entry 3 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,840 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:23 UTC |
SALEKI-GERHARDT AZITAEVP, Operations
|
GrantCommon Stock, $0.01 par value | 4,279 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002050 · edgar.xml · nonDerivative · entry 2 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,272 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:23 UTC |
SALEKI-GERHARDT AZITAEVP, Operations
|
GrantCommon Stock, $0.01 par value | 14,552 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002050 · edgar.xml · nonDerivative · entry 1 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,993 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:23 UTC |
RICHMOND TIMOTHY J.EVP, Chief HR Officer
|
GrantOption(right to buy) · Derivative | 42,236 | $0.00 Strike: $105.92 | $0.00 |
DisclosureSEC source: 0001179110-21-002051 · edgar.xml · derivative · entry 5 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,236 Underlying: Common stock · 42,236 shares Expires 2031-02-17 F5 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 14,079 on February 18, 2022, 14,079 on February 18, 2023, and 14,078 on February 18, 2024. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:23 UTC |
RICHMOND TIMOTHY J.EVP, Chief HR Officer
|
GrantCommon Stock, $0.01 par value | 11,978 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002051 · edgar.xml · nonDerivative · entry 4 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,038 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:23 UTC |
RICHMOND TIMOTHY J.EVP, Chief HR Officer
|
GrantCommon Stock, $0.01 par value | 4,998 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002051 · edgar.xml · nonDerivative · entry 3 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,060 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:23 UTC |
RICHMOND TIMOTHY J.EVP, Chief HR Officer
|
GrantCommon Stock, $0.01 par value | 4,105 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002051 · edgar.xml · nonDerivative · entry 2 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,062 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:23 UTC |
RICHMOND TIMOTHY J.EVP, Chief HR Officer
|
GrantCommon Stock, $0.01 par value | 13,957 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002051 · edgar.xml · nonDerivative · entry 1 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,957 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 18:25 UTC |
Michael Robert A.EVP, Chief Financial Officer
|
GrantOption(right to buy) · Derivative | 65,217 | $0.00 Strike: $105.92 | $0.00 |
DisclosureSEC source: 0001179110-21-002052 · edgar.xml · derivative · entry 5 Michael Robert A. · CIK 0001699914 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,217 Underlying: Common Stock · 65,217 shares Expires 2031-02-17 F5 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 21,739 on February 18, 2022, 21,739 on February 18, 2023, and 21,739 on February 18, 2024. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 18:25 UTC |
Michael Robert A.EVP, Chief Financial Officer
|
GrantCommon Stock, $0.01 par value | 16,220 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002052 · edgar.xml · nonDerivative · entry 4 Michael Robert A. · CIK 0001699914 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,883 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 18:25 UTC |
Michael Robert A.EVP, Chief Financial Officer
|
GrantCommon Stock, $0.01 par value | 8,859 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002052 · edgar.xml · nonDerivative · entry 3 Michael Robert A. · CIK 0001699914 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,663 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 18:25 UTC |
Michael Robert A.EVP, Chief Financial Officer
|
GrantCommon Stock, $0.01 par value | 1,485 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002052 · edgar.xml · nonDerivative · entry 2 Michael Robert A. · CIK 0001699914 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,804 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 18:25 UTC |
Michael Robert A.EVP, Chief Financial Officer
|
GrantCommon Stock, $0.01 par value | 5,049 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002052 · edgar.xml · nonDerivative · entry 1 Michael Robert A. · CIK 0001699914 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,319 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:25 UTC |
Gosebruch Henry OEVP, Chief Strategy Officer
|
GrantOption(right to buy) · Derivative | 49,068 | $0.00 Strike: $105.92 | $0.00 |
DisclosureSEC source: 0001179110-21-002053 · edgar.xml · derivative · entry 7 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,068 Underlying: Common Stock · 49,068 shares Expires 2031-02-17 F7 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 16,356 on February 18, 2022, 16,356 on February 18, 2023, and 16,356 on February 18, 2024. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:25 UTC |
Gosebruch Henry OEVP, Chief Strategy Officer
|
GrantCommon Stock, $0.01 par value | 14,724 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002053 · edgar.xml · nonDerivative · entry 4 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,544 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:25 UTC |
Gosebruch Henry OEVP, Chief Strategy Officer
|
GrantCommon Stock, $0.01 par value | 7,972 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002053 · edgar.xml · nonDerivative · entry 3 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,820 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:25 UTC |
Gosebruch Henry OEVP, Chief Strategy Officer
|
GrantCommon Stock, $0.01 par value | 6,555 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002053 · edgar.xml · nonDerivative · entry 2 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,848 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:25 UTC |
Gosebruch Henry OEVP, Chief Strategy Officer
|
GrantCommon Stock, $0.01 par value | 22,287 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002053 · edgar.xml · nonDerivative · entry 1 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,293 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 22:00 UTC |
RAPP EDWARD JDirector
|
GrantStock Equivalent Units · Derivative | 328 | $107.05 Strike: $0.00 | $35,112.40 |
DisclosureSEC source: 0001179110-21-000193 · edgar.xml · derivative · entry 1 RAPP EDWARD J · CIK 0001171780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,289 Underlying: Common Stock · 328 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.